Skip to Content

Press Release

Appointment of Non-Executive Director

November 24, 2015 at 7:00 AM GMT

Released : Nov 24, 2015

RNS Number : 6973G

Tiziana Life Sciences PLC

24 November 2015



Tiziana Life Sciences plc

("Tiziana" or "the Company")


Appointment of Non-Executive Director


London, 24 November 2015 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announces that has appointed Willy Simon as a non-executive director. Mr Simon brings the benefit of a long and successful career as a banker.


Willy Jules Simon, aged 64, is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. From 2004 until 2012, he served as a non-executive director of Redi & Partners Ltd., a fund of funds. He was previously chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2015 and had been a director of Playlogic Entertainment Inc., a NASDAQ OTC listed company.


Gabriele Cerrone, Executive Chairman of the Company commented: "I am delighted that Willy Simon has agreed to join the Board of Tiziana Life Sciences. Willy's career as a senior banker and as a director of other publicly listed companies gives him a wealth of experience which complements the skills of the existing Board."




Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder


+44 (0)20 7493 2853

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Avi Robinson


+44 (0)20 7148 7900

Beaufort Securities Limited (Broker)

Saif Janjua


+44 (0)20 7382 8300

FTI Consulting

Simon Conway / Rob Winder / Natalie Garland-Collins

+44 (0)20 3727 1000



AIM Disclosures


Further disclosures on Willy Simon as required under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies are as follows:


The directorships and / or partnerships held by Willy Simon in the previous five years are as follows:




A.I.A Ltd


Velox3 Plc (formerly 24/7 Gaming Group Holdings plc)

 Bever Holding N.V.

24/7 Gaming Group N.V.

Monldee Finance B.V.

A.I.A BV Netherlands

Nantucket Energy Limited

Playlogic Entertainment Inc

West African Minerals Corporation



There are no further disclosures in relation to Willy Simon pursuant to Schedule 2(g) of the AIM Rules for Companies.



About Tiziana Life Sciences


Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology.


In January 2015, the Company entered into an exclusive license from Nerviano Medical Sciences relating to milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy.


The Company also in-licensed another clinical asset in December 2014 from Novimmune. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II asset has potential application in a wide range of autoimmune and inflammatory diseases, such as multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.


Tiziana Life Sciences' research team has discovered that Bcl-3 has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease.


For more information go to 


This information is provided by RNS

The company news service from the London Stock Exchange